Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,014 INR | -0.41% | -0.77% | +25.09% |
09/04 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
27/03 | NATCO Pharma Limited Announces Board Appointments | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's enterprise value to sales, at 4.25 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.09% | 2.18B | C | ||
+33.25% | 699B | C+ | ||
+28.59% | 571B | B | ||
-3.55% | 364B | C+ | ||
+18.16% | 326B | B- | ||
+4.36% | 286B | C+ | ||
+14.81% | 236B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NATCOPHARM Stock
- Ratings NATCO Pharma Limited